News

BARDA and GeneSpark Diagnostics, Inc. entered into a partnership to develop a rapid diagnostic test for use on the GeneSpark GeneSparkTM molecular diagnostic system to detect the SARS-CoV-2 virus with results available within an hour. Results are provided to users and integrated into a cloud-based mobile platform that can convey de-identified test results to public …

Continue reading "BARDA and GeneSpark Diagnostics, Inc. Entered Into a Public-Private Partnership to Develop a Rapid Diagnostic Test for SARS-CoV-2"

BRANFORD, Conn.--(BUSINESS WIRE)--The U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) awarded GeneSpark Diagnostics, Inc. the second phase of a contract to develop a field-deployable Anthrax diagnostic assay and expand the research to an antimicrobial resistance diagnostic assay. The BARDA contract with GeneSpark Diagnostics is, potentially, a 3.5-year project, …

Continue reading "GeneSpark Diagnostics Awarded Expanded Second Phase of Contract"

BRANFORD, Conn.--(BUSINESS WIRE)--GeneSpark Diagnostics, Inc., a molecular diagnostic company located in Branford, Connecticut, announced that it has closed a $9 million Series A equity round led by Connecticut Innovations (CI), with participation of current and new stockholders, including VC23, Axiom, and Leading Edge Ventures. The financing proceeds will be used to accelerate the company’s innovative …

Continue reading "GeneSpark Diagnostics Announces $9 Million Series A Financing to Accelerate Development of Disruptive Molecular Diagnostic Platform"

October 15, 2018.  (Branford, CT) Richard Birkmeyer, PhD, selected as President and CEO of GeneSpark Diagnostics, Inc. Richard “Rick” Birkmeyer, PhD, has been chosen as the President and CEO of GeneSpark Diagnostics, Inc.  Before joining GeneSpark Diagnostics, Rick was CEO at CD Diagnostics, Inc. The company developed synovial fluid biomarkers using immunoassay technology which have …

Continue reading "(Branford, CT) Richard Birkmeyer, PhD, Selected as President and CEO of GeneSpark Diagnostics, Inc."

BRANFORD, CONN. (PRWEB) DECEMBER 19, 2017 The U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), has awarded GeneSpark Diagnostics a contract to develop a field-deployable Anthrax diagnostic assay. This contract will advance and expand the ability to combat the threat of Bacillus anthracis by utilizing the GeneSparkDxTM Molecular Diagnostic …

Continue reading "GeneSpark Diagnostics Awarded Contract to Develop a Field-Deployable Anthrax Diagnostic Assay"

The grant will fund the development of specific primers to identify 15 different SNPs in the TB genome that confer resistance to front line TB antibiotics. The drug sensitivity test will be added into the existing GeneSpark TB assay to create a panel that will include accurate diagnosis of TB along with comprehensive drug sensitivity …

Continue reading "GeneSpark Diagnostics Awarded a Phase I SBIR Grant from the NIH to Develop a Rapid Molecular Assay for Detection of Multiple Drug Resistant TB from Sputum"

A U.S. Securities Exchange Commission filing shows Branford-based GeneSpark Diagnostics, Inc. has raised $2 million in equity and hopes to sell another $1 million. To date, eight investors have purchased equity in the biotechnology company that is working on a better means of diagnosing tuberculosis around the world. Connecticut Innovations approved a $150,000 investment in …

Continue reading "GeneSpark Diagnostics Raises $2M in Equity Funding"